Document is current
Any future updates will be listed below
-
Authors
Biechele, Gloria
Franzmeier, Nicolai
Blume, Tanja
Ewers, Michael
Luque, Jose Medina
Eckenweber, Florian
Sacher, Christian
Beyer, Leonie
Ruch-Rubinstein, Francois
Lindner, Simon
Gildehaus, Franz-Josef
von Ungern-Sternberg, Barbara
Cumming, Paul
Bartenstein, Peter
Rominger, Axel
Höglinger, Günter U.
Herms, Jochen
Brendel, Matthias http://orcid.org/0000-0002-9247-2843
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (BR4580/1-1, RO5194/1-1, EXC 2145 SyNergy)
- License Information
-
More Information
Article History
Received: 20 July 2020
Accepted: 25 November 2020
First Online: 14 December 2020
Ethics approval and consent to participate
: All experiments were carried out in compliance with the National Guidelines for Animal Protection, Germany, and following the guidelines of the EU Directive 2010/63/EU. Experiments were approved by the regional Animal Care Committee of the Government of Oberbayern (Regierung Oberbayern) and were overseen by a veterinarian.
: Not applicable.
: G.U.H. received research support from GE Healthcare and Neuropore; has ongoing research collaborations with Orion and Prothena; serves as a consultant for AbbVie, AlzProtect, Asceneuron, Biogen, Biohaven, Lundbeck, Novartis, Roche, Sanofi, and UCB; received honoraria for scientific presentations from AbbVie, Biogen, Roche, Teva, UCB, and Zambon; and holds a patent on PERK Activation for the Treatment of Neurodegenerative Diseases (PCT/EP2015/068734). M.B. received speaking honoraria from Life Molecular Imaging and GE healthcare. M.B. is an advisor of Life Molecular Imaging. All other authors report no conflicts of interest.
